Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Protagenic Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +1 vs. Q3 2022
- Shares held
- 611.4K
- +13.4K (+2.2%) vs. Q3 2022
- Total value
- $247.9K
- −$94.1K (−27.5%) vs. Q3 2022
- New holders
- 2
- 3 more added
- Sold out
- 1
- 5 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $25.4K |
| Q1 2026 | 4 | $44.4K |
| Q4 2025 | 12 | $150.9K |
| Q3 2025 | 11 | $344.4K |
| Q2 2025 | 11 | $258.1K |
| Q1 2025 | 9 | $65.9K |
| Q4 2024 | 9 | $75.0K |
| Q3 2024 | 11 | $104.3K |
| Q2 2024 | 11 | $145.7K |
| Q1 2024 | 11 | $205.6K |
| Q4 2023 | 10 | $106.8K |
| Q3 2023 | 9 | $179.5K |
| Q2 2023 | 10 | $198.4K |
| Q1 2023 | 10 | $164.2K |
| Q4 2022 | 18 | $247.9K |
| Q3 2022 | 17 | $342.0K |
| Q2 2022 | 16 | $435.0K |
| Q1 2022 | 17 | $548.0K |
| Q4 2021 | 19 | $1.32M |
| Q3 2021 | 19 | $1.81M |
| Q2 2021 | 13 | $683.0K |
| Q1 2021 | 1 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Protagenic Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 236,309 | $94.5K | 0.00% | −16,516−6.5% | Reduced |
| Geode Capital Management, LLC | 103,595 | $43.0K | 0.00% | −284−0.3% | Reduced |
| FNY Investment Advisers, LLC | 75,000 | $31.0K | 0.04% | 00.0% | Unchanged |
| State Street Corp | 55,246 | $23.1K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 23,482 | $9.81K | 0.00% | +7,352+45.6% | Added |
| Northern Trust Corp | 22,485 | $8.99K | 0.00% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 20,000 | $8.00K | 0.00% | +20,000 | New |
| UBS Group AG | 17,153 | $6.86K | 0.00% | +10,676+164.8% | Added |
| Concorde Asset Management, LLC | 16,718 | $6.69K | 0.01% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 13,977 | $5.84K | 0.00% | +13,977 | New |
| Virtu Financial LLC | 10,110 | $4.00K | 0.00% | −470−4.4% | Reduced |
| Advisor Group Holdings, Inc. | 11,055 | $4.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,206 | $2.00K | 0.00% | −321−4.9% | Reduced |
| Wells Fargo & Company | 90 | $36 | 0.00% | +2+2.3% | Added |
| Bank of America Corp | 4 | $2 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1 | $0 | 0.00% | −1−50.0% | Reduced |
| Harbor Investment Advisory, LLC | 1 | $0 | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 3 | $0 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −21,025−100.0% | Sold out |